Protective effect of milk fat globule-epidermal growth factor-factor VIII after renal ischemia-reperfusion injury in mice
A Matsuda, R Wu, A Jacob, H Komura… - Critical care …, 2011 - journals.lww.com
Critical care medicine, 2011•journals.lww.com
Objectives: Renal ischemia-reperfusion injury causes acute renal failure, and the hallmarks
of renal ischemia-reperfusion injury are inflammation, apoptosis, necrosis, and capillary
dysfunction. Milk fat globule-epidermal growth factor-factor VIII (MFG-E8), a membrane-
associated secretory glycoprotein, is produced by immune cells and reported to participate
in multiple physiologic processes associated with tissue remodeling. We have recently
shown that MFG-E8 treatment attenuates organ injury, inflammatory responses, and survival …
of renal ischemia-reperfusion injury are inflammation, apoptosis, necrosis, and capillary
dysfunction. Milk fat globule-epidermal growth factor-factor VIII (MFG-E8), a membrane-
associated secretory glycoprotein, is produced by immune cells and reported to participate
in multiple physiologic processes associated with tissue remodeling. We have recently
shown that MFG-E8 treatment attenuates organ injury, inflammatory responses, and survival …
Abstract
Objectives:
Renal ischemia-reperfusion injury causes acute renal failure, and the hallmarks of renal ischemia-reperfusion injury are inflammation, apoptosis, necrosis, and capillary dysfunction. Milk fat globule-epidermal growth factor-factor VIII (MFG-E8), a membrane-associated secretory glycoprotein, is produced by immune cells and reported to participate in multiple physiologic processes associated with tissue remodeling. We have recently shown that MFG-E8 treatment attenuates organ injury, inflammatory responses, and survival after sepsis through the enhancement of phagocytosis of apoptotic cells. The purpose of this study was to determine whether administration of MFG-E8 attenuates renal ischemia-reperfusion injury.
Design:
Prospective, controlled, and randomized animal study.
Setting:
A research institute laboratory.
Subjects:
Male C57BL/6J mice (20–25 g).
Interventions:
Renal ischemia-reperfusion injury with bilateral renal pedicle clamping for 45 mins, followed by reperfusion. A recombinant murine MFG-E8 (0.4 μg/20 g) was given intraperitoneally at the beginning of reperfusion.
Measurements and Main Results:
MFG-E8 levels, organ injury variables, inflammatory responses, histology, apoptosis, and capillary functions were assessed at 1.5 and 20 hrs after reperfusion. A 60-hr survival study was conducted in MFG-E8−/− and recombinant murine MFG-E8-treated wild-type mice. After renal ischemia-reperfusion injury, MFG-E8 mRNA and protein expressions were significantly decreased in the kidneys and spleen. Treatment with recombinant murine MFG-E8 recovered renal dysfunction, significantly suppressed inflammatory responses, apoptosis, necrosis, and improved capillary functions in the kidneys. In the survival study, MFG-E8−/− mice showed a significant deterioration and, in contrast, recombinant murine MFG-E8-treated wild-type mice showed a significant improvement of survival compared with vehicle-treated wild-type mice.
Conclusions:
MFG-E8 can be developed as novel treatment for renal ischemia-reperfusion injury. This protective effect appears to be mediated through the enhancement of apoptotic cell clearance and improvement of capillary functions in the kidneys.
Lippincott Williams & Wilkins